NEOG · Neogen Corporation

Current Thesis

Neogen’s turnaround thesis rests on Food Safety growth and debt reduction, with the October results testing operating progress and the Genomics sale determining whether the funding arrives. The 2026-07-30 results established the operating case; the investor day announced on 2026-09-08 adds a confirmed 2026-10-07 examination of management’s transformation plan. That event advances the calendar since the August coverage without establishing another quarter of improvement. Neogen announcement

The measured price evidence remains mixed: the 2026-09-11 adjusted close was $11.78, above the 2026-08-28 close of $11.66 but below the 2026-08-21 close of $11.95. The narrative is maturing — an inference dated by Piper Sandler’s 2026-08-26 upgrade and the subsequent investor-day announcement, while the latest close remains below the supplied $12.15 annual high. These observations do not establish widening participation.

The case would be confirmed by quarterly revenue and earnings meeting management’s July guidance, followed by completion of the divestiture and delivery of the stated year-end leverage objective. A weekly close below $11.00 invalidates the price structure; a revenue miss or loss of the divestiture funding independently breaks the corresponding operating or balance-sheet claim.

Bullish and bearish views on Neogen Corporation

The model's bull view on Neogen Corporation (NEOG), in brief: Food Safety supplied operating evidence. The bear view: The earnings improvement remains limited. Both cases follow in full.

Bull Case

• Food Safety supplied operating evidence. Neogen’s 2026-07-30 earnings presentation reported fiscal fourth-quarter Food Safety revenue of $166.8 million and core growth of 5.8%. This supports the recovery thesis, but a single quarter cannot establish its durability.
• Quarterly earnings supported the recovery. The 2026-07-30 release reported total revenue of $225.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $45.4 million, representing a 20.2% margin.
• Management set measurable operating hurdles. On 2026-07-30, Neogen guided fiscal 2027 revenue to $880–885 million and adjusted EBITDA to $180–182 million. Those ranges provide an explicit test; a reduction below their lower bounds would contradict the improvement case.
• Debt reduction has identified funding. Management’s 2026-07-30 presentation identified approximately $140 million of expected net proceeds from the $160 million Genomics sale, mainly for debt reduction. The funding case fails if the transaction cannot deliver those proceeds.

Bear Case

• The earnings improvement remains limited. The 2026-07-30 presentation reported fiscal 2026 adjusted EBITDA of $177.8 million against fiscal 2027 guidance of $180–182 million. The guidance supports improvement but does not establish a large increase in annual earnings.
• Regulatory clearance remains unresolved. The Australian Competition and Consumer Commission (ACCC) register status documented on 2026-08-30 placed the Genomics transaction in detailed assessment, with a 2026-11-27 decision due date. That is a regulatory deadline, not evidence of approval or completed funding.
• Debt precedes the anticipated proceeds. Neogen reported gross debt of $794 million and cash of $186 million at 2026-05-31. Those historical balances establish why completion matters; they do not establish the current cash balance.
• Analyst support has not established a breakout. Piper Sandler raised its rating to Overweight and its target to $14 on 2026-08-26. The 2026-09-11 adjusted close of $11.78 remained below the supplied $12.15 annual high; that comparison cannot identify who bought or sold.

Setup & Price Structure

At 2026-09-11, the adjusted daily close was $11.78, the shares were up 29.5% over three months, and the close was 3.0% below the $12.15 annual high. The 14-day relative strength index was 44.4. These are measured price observations; neither a rising moving average nor its distance from price is supplied.

The existing $11.00 weekly-close threshold remains the published structural invalidation. It sits below the documented post-results closes of $11.47 on 2026-08-07 and $11.95 on 2026-08-21; the available observations do not establish that it is a repeatedly tested support shelf. A weekly close above the $12.15 reference high would overturn the present finding that the breakout remains unconfirmed.

Retail-facing attention includes Zacks’ 2026-09-10 article discussing innovation, manufacturing and deleveraging. This is an observable instance of coverage, not a measure of investor positioning. The sample is too small to support a crowding claim, and no dated short-interest, fund-flow or insider-transaction evidence is available here. Zacks coverage

Catalyst Calendar (next 30 days)

• 2026-10-01 — Annual shareholder meeting. The 2026-08-21 proxy schedules director elections and the executive-compensation vote. It is a governance event; the proxy does not establish an operating update.
• 2026-10-07 — Confirmed investor day. Neogen’s 2026-09-08 announcement schedules presentations on commercial execution, innovation and operations. Specific financial commitments could make the transformation case more testable; presentations alone would not establish delivery. Company announcement
• ~2026-10-08, est. Fiscal first-quarter results. Public calendars estimate this date; company confirmation remains missing. Management’s 2026-07-30 hurdles are revenue of $207–209 million and approximately $37 million of adjusted EBITDA. Revenue below $207 million would fail the stated quarterly operating test. Estimated earnings calendar
• 2026-11-27 — Later funding decision. The ACCC deadline documented on 2026-08-30 matters because the proposed Genomics sale supplies the expected debt-reduction proceeds. An extension would defer resolution; a prohibition would break the funding thesis.

What Would Change Our Mind

Loss of the post-results price structure would end this version of the thesis through a weekly close below $11.00. This is an analytical condition, anchored to the previously published threshold and the August closes, rather than a claim that the market has repeatedly defended that exact price.

Operating confirmation requires the next quarterly report to meet the 2026-07-30 revenue range of $207–209 million and approximately $37 million of adjusted EBITDA. Revenue below $207 million or annual adjusted EBITDA guidance below $180 million would contradict the stated improvement case.

The funding leg requires transaction completion within management’s stated window ending 2026-11-30 and net leverage below three times adjusted EBITDA by 2026-12-31. Failure to close by that window would invalidate the timing claim; regulatory prohibition or withdrawal of the leverage objective would invalidate the funded-deleveraging thesis.

Correlation Notes

The 2026-07-30 Food Safety results and proposed Genomics proceeds make this a single-company operating and financing case. No paired peer or index return series is available to establish that the 29.5% three-month price increase through 2026-09-11 reflects a group move.

Zoetis is linked through the proposed $160 million transaction described in Neogen’s 2026-07-30 materials. That establishes a transaction dependency, not a measured correlation between the companies’ share prices.